Nesiritide: A reappraisal of efficacy and safety

Sanjiv J. Shah, John R. Teerlink*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


The treatment of acute decompensated heart failure (ADHF) remains a therapeutic challenge. Nesiritide was approved by the FDA in 2001 for the treatment of patients with ADHF who have dyspnea at rest or with minimal exertion. Although widely adopted for the treatment of ADHF due to its ability to decrease ventricular filling pressures and to provide mild symptomatic benefit, recent analyses have suggested that nesiritide worsens renal function and increases mortality. Although some discount these analyses that demonstrate the potential dangers of nesiritide, others have stated that its use at the present time must be weighed against the possibility of worse outcomes. A large outcomes trial in patients with ADHF would help clarify the role of nesiritide.

Original languageEnglish (US)
Pages (from-to)361-369
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Issue number3
StatePublished - Feb 2007


  • Congestive heart failure
  • Natriuretic
  • Nesiritide
  • Peptide
  • Renal insufficiency

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Nesiritide: A reappraisal of efficacy and safety'. Together they form a unique fingerprint.

Cite this